ARTICLE | Tools & Techniques

Vical advisor makes a point

November 15, 1993 8:00 AM UTC

University of Chicago researcher Jeffrey Leiden's work on the delivery of therapeutic proteins using a variety of gene delivery techniques ultimately could result in new product candidates for Vical Inc.

Leiden, who is a member of VICL's scientific advisory board and whose work is funded by VICL, made a splash at last week's American Heart Association meeting with a report that he successfully delivered erythropoietin (EPO) in animals using myoblasts instead of viral vectors. VICL, which has already licensed some of Leiden's work, has an exclusive option to bid on his technology. Leiden is also working on replication incompetent adenoviruses...